Purified populations of natural killer (NK) cells were obtained from mice with severe combined immune deficiency (SCID). SCID spleen cells were cultured and activated with recombinant human interleukin-2 (rhlL-2) in vitro. The activated NK cells were then transferred with syngeneic BALB/c bone marrow cells (BMC) and rhlL-2 into lethally irradiated syngeneic recipients to determine their effect on long-term hematopoietic reconstitution. On analysis, the transfer of rhlL-2-activated NK cells along with BMC resulted in significant increases in splenic and BM hematopoietic progenitor cells when compared with those for mice not receiving NK cells. Histologic and flow cytometric analysis showed a marked increase in granulocytic and megakaryocytic lineage cells present in the spleens of the mice receiving activated NK cells. Analysis of the peripheral blood indicated that the transfer of activated NK cells with
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UTOLOGOUS BONE MARROW transplantation
A (ABMT) is currently used as a treatment for neoplastic diseases such as leukemia, lymphoma, and certain solid tumors.' However, there are several problems associated with ABMT that limit its efficacy including a period of immune deficiency which leaves the patient susceptible to infection and the recurrence of the cancer. 2 Natural killer (NK) cells are lymphoid cells that have the ability to lyse certain transformed cell lines in a non-major histocompatibility complex-restricted manner.3 NK cells have also been shown to exert antitumor effects both in vitro and in vivo.34 Additionally, NK cells have been shown to exert antiviral effects in v i~o .~,~
The presence of NK activity after allogeneic BMT has been shown to correlate with antitumor response^.^ However, the effects of activated NK cells transferred with BM cells (BMC) on long-term hematopoietic reconstitution after syngeneic BMT are not known.
NK cells have been shown to be bidirectional regulators of hematopoiesis. Activated NK cells have been shown to produce cytokines that inhibit and cytokines that promote hematopoiesis in vitro.8 It had been shown that, when BMC are placed in soft agar with activated NK cells under optimal growth conditions, the NK cells produced an inhibitory effect. However, when BMC and activated NK cells were placed in soft agar under limiting conditions, the NK cells exerted a stimulatory effect on hematopoietic growth. ' We recently reported that activated NK cells promote shortterm BMC engraftment when transferred along with BMC into lethally irradiated syngeneic mice.* We now extend these findings and report that after transfer of activated NK cells with BMC, there is a significant increase in hematopoietic engraftment shortly after the BMT as well as an improved long-term hematopoietic reconstitution primarily affecting granulocytic and megakaryocytic lineages. These results suggest that the transfer of activated NK cells with BMC may be of clinical use during ABMT.
MATERIALS AND METHODS
Mice. BALB/cJ (H-2d) and CB17 scidlscid (SCID, H-2d) were obtained from the Animal Production Facility (National Cancer BMC also significantly improved platelet and total white blood cell counts, with increases in segmented neutrophils. Erythroid recovery was not affected. Finally, lethally irradiated mice receiving activated NK cells and rhlL-2 along with limiting numbers of syngeneic BMC showed a marked increase in survival rate. These results show that the use of populations enriched for activated NK cells after syngeneic BM transplantation (BMT) has a profound enhancing effect on engraftment primarily affecting megakaryocytic and granulocytic cell reconstitution. Therefore, the transfer of activated NK cells and rhlL-2 may be of clinical use to promote hematopoietic reconstitution after BMT. This is a US government work. There are no restrictions on its use.
Institute-Fredrick Cancer Research and Development Center [NCI-FCRDC] Frederick, MD). SCID mice were housed under pathogen-free conditions and were administered neomycin sulfate (Biosol liquid UpJohn, Kalamazoo, MI) at 200 mg ( I mL) in 500 mL of tap water. SCID mice were used at 6 to 8 weeks of age. BALB/c mice were used at 8 to 12 weeks of age.
Propagation of NK cells and marker analysis. NK cells were prepared from the spleens, femurs, tibias, and vertebrae of 6-to 8-week-old SCID mice using culture conditions different than those we had previously used. 8 The spleen cells (SC) and BMC were suspended in a sterile NK media containing 1,000 U/mL of recombinant human interleukin-2 (rhIL-2; Cetus, Emeryville, CT), RPMI 1640 and 1% NTC109 (both from Whittaker Bio Products, Walkersville, MD), 10% fetal bovine serum (FBS; Inovar Chemicals, Gaithersburg, MD), I% L-glutamine and I% pen-strep (both from GIBCO, Grand Island, NY), 4% the TI50 flasks. The supernatants from the flasks were poured off and collected. A total of 10 mL of Hanks Balanced Salt Solution (HBSS)-calcium and magnesium free (Cell Gro; Mediatech, Herndon, VA) was added to each flask. The flasks were rapped vigorously to detach cells, and supernatants were collected. Flasks were washed again with HBSS, and supernatants were collected. All supernatants were then centrifuged at 1,600 rpms for 6 minutes. Pellets were pooled. These cells were then layered over FBS. This was centrifuged at 1,600 rpms for 6 minutes. Pellets were then resuspended in an appropriate volume of media, and cells were counted on a Coulter counter (Coulter, Hialeah, FL). Cells were then incubated with the appropriate antibodies as previously The monoclonal antibodies (MoAbs) used were 8C5 (a marker found on murine granulocytes),loS" anti-L3T4 (anti-CD4), antiLyt-2 (anti-CDS), anti-Thy 1. Cell mediated cytotoxicity assay. NK lytic activities were assessed by incubating varying numbers of effector cells with 5 X IO3 51Cr (New England Nuclear, Boston, MA)-labeled YAC-1 tumor cells in U-bottom, 96-well plates (Falcon; Becton Dickinson) at 37°C for 4 hours in RPMI 1640 medium supplemented with 10% FBS, gentamicin (50 pg/mL), L-glutamine (200 mmol/L), and 1 mol/L Hepes buffer. Supernatants were removed from the wells with a Cambridge PHD harvester and counted on the LKB gamma counter (Pharmacia, Uppsala, Sweden). Percent specific cytotoxicity was calculated by the following formula:
Irradiation andpretreatment of mice. Recipient BALB/cJ mice were exposed to 137Cs y irradiation source. The mice received 800 to 950 cGy total irradiation. Mice in some groups received only 5 X IO5 BALB/c BMC intravenously (IV). Mice in other groups also received 2 X IO' SCID NK cells intraperitoneally (IP) that had been in culture with rhIL-2 for 7 to I O days. The mice then received 50,000 U rhIL-2 in 0.2 mL PBS IP once a day on days 0, 1, and 2 after BMC transfer. The groups consisted of irradiation only, BMC only, BMC with rhIL-2, and BMC with rhIL2 and NK cells. On day 7 after BMT, mice were reinjected with NK cells and rhIL-2 IP. IL-2 was administered on days 7,8, and 9. Mice not receiving IL-2 were injected with 0.2 mL of HBSS. All experiments were assayed with 3 to 4 mice/group and were performed 3 to 6 times with a representative experiment being shown.
Assay for in vitro hematopoiesis. BMC and SC from mice 12 days after BMT were washed and resuspended in Iscove's modified Dulbecco's medium (IMDM) with 15% FBS, 1% L-glutamine, 2 X mol/L 2-mercaptoethanol, and antibiotics (complete IMDM). SC were plated at I X IO6 cells/plate, and BMC were plated at 1 X lo5 cells/plate. Both SC and BMC were plated with 0.35% Sea Plaque (FMC BioProducts, Rockville, MD) in 35-mm X IO-" plates with grid (NUNC, Naperville, IL). Colony growth was stimulated with optimal doses ofthe growth promoting cytokines recombinant mouse granulocyte-macrophage colony-stimulating factors (GM-CSF 10 ng/mL) and recombinant mouse IL-3 ( I O ng/mL), supplied by the Biological Response Modifiers Program Repository (NCI-FCRDC). Plates were incubated at 37"C, 5% COz, and 100% humidity for 7 days. The plates were then examined for colonies, where greater than 50 cells constituted a colony.
In vitro depletion ofASGM1' cells. NK cells were cultured and harvested, as described above, and divided into 2 groups. The cells were incubated for 30 minutes on ice with anti-ASGMI (Wako Pure Chemical Industries Ltd, Richmond, VA) at a dilution of 150 (1 X IO7 c/mL) or with HBSS alone. The cells were then washed and resuspended in HBSS containing 1,000 U/mL of rhIL-2. Both groups of cells were then incubated at 37°C for 45 minutes with baby rabbit complement (a kind gift from Dr Dennis Taub, NCI-FCRDC) at a dilution of ]:I2 (1 X IO' c/mL). The cells were then washed 2 times with IL-2-containing media. The cells were analyzed by flow cytometric analysis to determine that greater than 90% of the ASGMl+ cells were removed by antibody and complement treatment. The cells were then injected into mice without readjusting the cell concentration.
On days 1 1, 1 5, and 19 after BMT, spleen tissues from 3 mice/group were fixed in 10% formalin and paraffin-embedded, and 4-pm sections were cut and stained with hematoxylin and eosin.
For analysis of PB, blood was collected from the lateral tail vein of the mice using EDTA as an anticoagulant. Complete blood cell counts were performed with a Coulter counter (Coulter), and differential cell counts were performed by microscopic examination of Wright's stained PB smears (MetPath, Inc, Rockville, MD).
Histology.
Analysis ofperipheral blood (PB). Varying numbers of effector cells were incubated with 5 X 1 O3 "Cr-labeled NK-sensitive YAC-1 tumor target cells for 4 hours. Supernatants were collected and counted on a y radiation counter as described in the Materials and Methods.
For ll ASGMl+ cells were removed by anti-ASGM1 and complement treatment as described in the Materials and Methods.
# Values significantly (P < .001) lower than those for mice receiving BMC and rhlL-2 or BMC, NK cells, and rhlL-2.
administered 850 cGy, and mice in experiment B were administered 800 cGy.
Survival studies. Recipient BALB/cJ mice were exposed to 137Cs y irradiation source. The mice received 950 cGy total irradiation. Mice in some groups received 2 X lo5 BALB/c BMC IV. Mice in other groups received either BMC and 50,000 U rhIL-2 or BMC, rhIL-2, and 2 X lo7 NK cells. In some experiments mice received 2 X lo7 NK cells with rhIL-2 without BMC. Mice were then observed for several weeks, and moribund mice were killed. Three experiments were performed with 6 to 10 mice/group, with a representative experiment being shown.
Statistical analysis. A Student's t-test was performed to determine if values were significantly different (P < .001). A Wilcoxon rank-sum test was performed on the survival studies to determine if treatments were significantly different (P < .05).
RESULTS

NK cells cultured in vitro with rhIL-2 maintain a homogeneous phenotype.
SC and BMC from SCID mice were cultured in vitro with rhIL-2 for 7 to 10 days to obtain pure populations of NK cells. SCID SC and BMC were used to culture NK cells because SCID mice have no T or B cells because of a defect in their recombinase system and cannot rearrange their T-cell receptor or Ig However, SCID mice have normal NK cells and NK cell function." Because of a change in previous culture conditions to allow for the generation of large numbers of NK cells, the cultured cells were then analyzed with respect to phenotype and function. Through flow cytometric analysis, it was determined that the cultured NK cells were 87.6% Thy-1 positive and were negative for CD3, CD4, and CD8 surface markers. The cells were greater than 85% positive for ASGM1, greater than 75% positive for the Fc receptor for Ig (FcR), and negative for the macrophage marker, MAC-I (Table 1) . These results are consistent with the phenotype of activated NK cells.8~10~'2 The lytic capability of the cells was also determined in a 5'Cr-release cytotoxicity assay. The activated NK cells were found to be highly lytic against the NK-sensitive tumor target, YAC-1 (Table 2) , which is consistent with the phenotypic analysis showing that the majority of the cultured cells are activated NK cells.
Activated NK cells promote marrow engraftment ofsyngeneic BMC in lethally irradiated recipients. The activated
NK cells were then adoptively transferred along with BMC into lethally irradiated syngeneic recipients on day 0 to determine their effect on engraftment. NK cells were then administered again on day 7. rhIG2 was also administered daily for 3 days after each injection ofthe activated NK cells for the NK cells to maintain their function in vivo. Some mice received BMC alone, others received BMC and rhIL-2, whereas others received BMC, rhIL-2, and NK cells. Previous studies had shown that NK cells alone, IL-2 alone, and NK cells plus IL-2 could not reconstitute hematopoiesis in lethally irradiated mice.'*'* Eleven days after BMT, hematopoietic progenitor cell content was determined from the BM and spleen. The results showed that the transfer of rhIL-2-activated NK cells along with BMC resulted in significant (P < .OO 1) increases in splenic and BMC hematopoietic colony formation and in an increase in total hematopoietic progenitor content when compared with those for mice in groups not receiving NK cells (Table 3) . To ascertain if the hematopoietic effects of the transferred cells were indeed due to NK cells, ASGMl+ cells were removed before cell transfer by antibody and complement. The results showed that the transfer of ASGM1-cells with BMC actually resulted in lower hematopoietic engraftment in the recipients as evidenced by the lower numbers of hematopoietic progenitor cells in the spleen (Table 3, experiment B) . Thus, it appears that the transfer of activated NK cells along with BMC can promote short-term marrow engraftment after syngeneic BMT.
Histologic examination of the spleen also showed an increase of hematopoietic progenitor cells present in recipi- ents receiving NK cells and rhIL-2. Twelve days after BMT, there was a dramatic increase in megakaryocytes and granulocyte precursors seen in the spleens of the mice receiving NK cells when compared with the levels in mice receiving BMC alone (Fig 1) . Phenotypic evaluation of the splenocytes through flow cytometric analysis indicates that there was a modest increase in granulocyte precursors in the spleens of mice receiving NK cells as evidenced by the increased percentage and total amount of splenic 8C5' cells, a surface marker present on granulocytic lineage cells (Fig  2) ." This would support the data found through histologic examination of the spleen at this time point. These results
For Transfer of activated NK cells in syngeneic BMT improves PB hematologic parameters. Analysis of the PB complete blood counts and differentials indicated that the transfer of activated NK cells with BMC significantly improved platelet counts as well as white blood cell (WBC) counts. Not only were the platelet precursors (megakaryocytes) seen in the spleen, but a significant increase (P < .001) in platelet counts in the PB was observed on day 15 after BMT (Fig 3) .
A significant increase (P < .001) in WBC count in the PB was also observed on day 14 after BMT (Fig 4) . The WBCs were then stained to determine their phenotype. A significant increase (P < .OO I ) in segmented cells was noted on day 14 after BMT ( Fig 5) . Hemoglobin levels and hematocrit were not significantly affected. Additionally, the transfer of irradiated NK cells did not affect long-term hematopoietic reconstitution (data not shown), in agreement with our previous report.* Thus, the transfer of activated NK cells after syngeneic BMT results in the enhanced recovery of PB platelets and granulocytes.
NK cells promote animal survival when transferred with limiting numbers ofBMC.
We then wished to determine if the activated NK cells were sufficiently active at promoting hematopoiesis in vivo to permit hematopoietic reconstitution and survival of lethally irradiated mice administered limiting numbers of BMC. All BALB/c mice given 950 R of y radiation without BMC died. Additionally, all mice receiving NK cells and IL-2 without BMC also died, which is 
-
comparable with radiation controls indicating that the cultured SCID cells were not contributing a source of hematopoietic stem cells (data not shown). This is in agreement with previous experiments that showed that the transfer of NK cells without BMC did not result in short-term hematopoietic recovery in irradiated recipients. Administration of 2 X lo5 BALB/c BMC rescued 20% of the irradiated recipients. Addition of IL-2-activated NK cells to the BMC rescued two-thirds of the irradiated mice. Thus, mice receiving NK cells had significantly (P < .05) better survival rates than those not receiving NK cells (Fig 6) . Interestingly, there were also improved survival rates in the mice receiving BMC and rhIL-2; however, the magnitude of the survival advantage associated with the use of rhIL-2 alone did not reach statistical significance. The data presented here indicate that the transfer of rhIL-2-activated NK cells along with BMC and rhIL-2 into lethally irradiated syngeneic mice promotes granulocytic and megakaryocytic reconstitution.
The mechanism by which rhIL-2-activated NK cells promote hematopoietic reconstitution is not yet clear. The stimulatory effects on hematopoiesis may be due to their ability to produce cytokines such as granulocyte-macrophage col- Other recent studies have determined that GM-CSF and IL-6 promote megakaryocyte colony formation in vitro and in V~V O . '~, '~ Our data support these findings because an increase in megakaryocytes in the spleen and increased platelet counts were noted in the blood of irradiated mice receiving BMC plus NK cells. Therefore, the production of GM-CSF and IL-6 by the NK cells (as previously demonstrated') may be promoting platelet recovery. In a clinical setting, systemic administration of these cytokines may produce toxic side effect^."^^' Therefore, the possible advantage of using NK cells in a clinical setting may be the reduction of the toxic side effects because of the local release of adequate amounts of the cytokines in the sites where the cytokines act. This type of cellular immunotherapy might then be more advantageous than systemic administration of pharmacologic doses of these cytokines.
Because NK cells possess hematopoietic growth-promoting effects as well as antitumor activity, it would be worthwhile to explore their use in a clinical setting such as ABMT. The problems associated with ABMT, including immune deficiency and recurrence of the cancer, may be decreased with the use of activated NK cells. Clinically, activated NK cells could be used in ABMT to increase engraftment and to remove residual tumor. Additionally, because NK cells show antiviral properties, the use of these cells may be bene- There have been contradictory reports involving the effect of activated NK cells on hematopoiesis. In part, this may be due to differences in the assay systems and to the fact that many NK cell preparations contain contaminating populations of T cells or the difference between allogeneic and syngeneic NK cells on BM, or the transplant conditions (suboptimal BM + NK cells help; optimal BM + NK cells suppress). Our studies were performed with highly purified populations of activated NK cells. It may be difficult to isolate pure populations of NK cells in humans due to the paucity of NK cells in the PB. Therefore, clinical studies might require the use of lymphokine activated killer (LAK) cells, which contain both T and NK cells. Experiments for examining the role of LAK cells in syngeneic BMT are underway. This is an important issue, because studies using human LAK cells showed inhibitory effects on hematopoiesis in vitro.Ig However, a recent study has shown that the transfer of LAK cells was not deleterious to hematopoietic reconstitution and survival rates after syngeneic BMT in mice.*' These results then suggest that adoptive immunotherapy may be of clinical use when ABMT is used in the treatment of cancer.
